BEGIN:VCALENDAR VERSION:2.0 PRODID:-//IBSAL - ECPv6.18.0//NONSGML v1.0//EN CALSCALE:GREGORIAN METHOD:PUBLISH X-WR-CALNAME:IBSAL X-ORIGINAL-URL:https://ibsal.es/en/ X-WR-CALDESC:Events for IBSAL REFRESH-INTERVAL;VALUE=DURATION:PT1H X-Robots-Tag:noindex X-PUBLISHED-TTL:PT1H BEGIN:VTIMEZONE TZID:UTC BEGIN:STANDARD TZOFFSETFROM:+0000 TZOFFSETTO:+0000 TZNAME:UTC DTSTART:20240101T000000 END:STANDARD END:VTIMEZONE BEGIN:VTIMEZONE TZID:Europe/Helsinki BEGIN:DAYLIGHT TZOFFSETFROM:+0200 TZOFFSETTO:+0300 TZNAME:EEST DTSTART:20250330T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0300 TZOFFSETTO:+0200 TZNAME:EET DTSTART:20251026T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0200 TZOFFSETTO:+0300 TZNAME:EEST DTSTART:20260329T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0300 TZOFFSETTO:+0200 TZNAME:EET DTSTART:20261025T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0200 TZOFFSETTO:+0300 TZNAME:EEST DTSTART:20270328T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0300 TZOFFSETTO:+0200 TZNAME:EET DTSTART:20271031T010000 END:STANDARD BEGIN:DAYLIGHT TZOFFSETFROM:+0200 TZOFFSETTO:+0300 TZNAME:EEST DTSTART:20280326T010000 END:DAYLIGHT BEGIN:STANDARD TZOFFSETFROM:+0300 TZOFFSETTO:+0200 TZNAME:EET DTSTART:20281029T010000 END:STANDARD END:VTIMEZONE BEGIN:VEVENT DTSTART;VALUE=DATE:20250326 DTEND;VALUE=DATE:20300604 DTSTAMP:20251114T074015Z CREATED:20250304T093623Z LAST-MODIFIED:20251114T074015Z UID:10002030-1742947200-1906761599@ibsal.es SUMMARY:Diverse and responsible health DESCRIPTION:The project “Diverse and Responsible Health” aims at the scientific dissemination of the IBSAL among the LGTBI+ population of Salamanca. Through a series of workshops scheduled throughout 2025\, various key issues for the health of this group will be addressed\, promoting a gender and diversity perspective in medical and scientific research. \nThese workshops\, led by the Eros Service of Asociación Iguales\, will have the participation of specialized professionals\, IBSAL research staff and collaborating entities. The program includes four sessions with the following topics: \n\n\n\n\nITS: Why do they always point the finger at us? – Analysis of sexually transmitted infections in the LGTBI+ population and the need for a person-centered approach.\n\n  \nDate: Wednesday\, March 26\, 2025\, at 7:00 p.m. \nPlace: La Vegatería (C/ Gütenberg\, 13\, 37007 Salamanca) \nIBSAL Researchers: Moncef Belhassen and Virginia Velasco \nFree admission \n  \n \n  \n\nChemSex: an emerging phenomenon or an old acquaintance? – Study of ChemSex and its impact on health from a community perspective.\n\n  \nMore information coming soon. \n  \n\nLifestyles in queer people – Promotion of healthy habits and analysis of health determinants in the LGTBI+ population.\n\n  \nMore information coming soon. \n  \n\nMental health: how to take better care of ourselves – Minority stress\, discrimination and other barriers that affect the mental health of minorities.\n\n  \nMore information coming soon. \n  \nEach workshop will combine the presentation of specialists in the field with the participation of IBSAL research staff\, bringing scientific research closer to the community. \nThe project has the collaboration of several local entities and is supported by the University of Salamanca\, the City Council of Salamanca and the IBSAL. URL:https://ibsal.es/en/evento/diverse-and-responsible-health/ LOCATION:La Vegatería\, 13 Gütenberg Street\, Salamanca\, Salamanca\, 37007\, Spain CATEGORIES:Disclosure ATTACH;FMTTYPE=image/png:https://ibsal.es/wp-content/uploads/2025/03/Logo-Iguales-Tagline-Color.png END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260101 DTEND;VALUE=DATE:20280102 DTSTAMP:20251124T061504Z CREATED:20251124T061504Z LAST-MODIFIED:20251124T061504Z UID:10002268-1767225600-1830383999@ibsal.es SUMMARY:PARTNERSHIP: European Partnership on One Health and Antimicrobial Resistance (OH AMR) DESCRIPTION:Features\nThe first joint transnational call for proposals from the EUP OHAMR Partnership on Antimicrobial Resistance\, titled “Treatments and Adherence to Treatment Protocols” \nThe goal of this call for proposals is to improve treatment success rates in patients\, animals\, and plants affected by bacterial or fungal infections by offering new treatment options while reducing the risk of resistance development across the various settings of the “One Health” approach . \nThe call for proposals is co-financed by the European Union and involves 37 funding organizations from 28 countries\, with a total estimated budget of more than 31 million euros. \nIn addition\, the following national and regional funding agencies are participating in this call for proposals: the Aragon Institute of Health Sciences (IACS)\, the State Research Agency (AEI)\, and the Carlos III Health Institute (ISCIII). \nRequirements\nProposals must address one of the following topics: \nTopic 1: Identify and develop new combination therapies using existing or innovative antimicrobials\, or antimicrobials in combination with adjunctive therapies\, to extend drug efficacy and combat resistance. \nTopic 2: Develop tools and methods to improve adherence to treatment protocols. \nTopic 3: Assess the impact of antimicrobials used in veterinary and agricultural settings on the risk of AMR transmission to humans and the environment\, to inform policies on restricting certain antimicrobials for human use. \n\nSubmission deadline.\nThe following table lists the different dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 18\, 2025\n\n\nDeadline for Pre-Proposals\nFebruary 2\, 2026\, (1:00 p.m. CET)\n\n\nNotification of the Results of the Pre-Proposal\nApril 29\, 2026\n\n\nDeadline for full proposals\nJune 17\, 2026\, (1:00 p.m. CET)\n\n\nFinal Funding Recommendation Announced\nOctober 30\, 2026\n\n\nProjects begin\nDecember 2026–April 2027\n\n\n\n  \n  URL:https://ibsal.es/en/evento/partnership-european-partnership-on-one-health-and-antimicrobial-resistance-oh-amr-2/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260101 DTEND;VALUE=DATE:20280102 DTSTAMP:20251124T120728Z CREATED:20251124T120728Z LAST-MODIFIED:20251124T120728Z UID:10002252-1767225600-1830383999@ibsal.es SUMMARY:ERA4HEALTH Partnership DESCRIPTION:Features\nThe ERA4HEALTH partnership has published a joint transnational call \, “Prevent-OO: Understanding and Preventing Overweight and Obesity” Mechanisms of their onset and progression\, neglected determinants\, and novel strategies for critical transitional periods in life. \nThe call for proposals seeks to identify and implement innovative and holistic preventive and public health strategies to address obesity\, taking into account environmental\, psychological\, and socioeconomic factors to promote healthier lifestyles. In addition\, ERA4Health fosters transnational and interdisciplinary collaborations with a translational approach to generate new knowledge and develop effective prevention strategies. \nThe call for proposals is co-financed by the European Union and involves 25 funding organizations from 20 countries\, with a total estimated budget of more than 18 million euros. \nIn addition\, the Carlos III Health Institute (ISCIII) is participating in this call for proposals as the national funding agency. \nRequirements\nApplications must cover only one of the two topics listed below and address at least one of the two specified subtopics (subtopic 1a and/or 1b for topic 1\, and subtopic 2a and/or 2b for topic 2); both topics and subtopics are equally relevant for this call: \n1. Understanding the causes of obesity and overweight and their complications through mechanistic research \n1a. To investigate biological mechanisms—including chronobiological\, genetic\, and/or epigenetic mechanisms—underlying the onset and progression of overweight and obesity\, as well as related diseases. Secondary factors that may influence these biological mechanisms—such as the living environment\, lifestyle\, or psychological status—should also be considered where relevant. \n1b. To investigate how being overweight and obesity contribute to the development of related clinical complications and/or affect the mechanism of action of treatments for other diseases or disorders. \n2. Prevention and public health strategies for critical transitional periods of life. Both subtopics 2a. and 2b. should address critical transitional periods of life only. The choice of the critical transitional periods of life to be studied must be clearly justified in the proposal. These periods should result from biological changes (e.g.\, postpartum\, menopause\, andropause) or socio-environmental changes (e.g.\, the period between pregnancies\, diagnosis of a chronic disease\, recovery from illness\, retirement\, etc.). \n2a. To understand and address neglected determinants—including their interdependence—in the onset and progression of overweight and obesity during transitional periods of life. \n2b. To develop novel tools or preventive strategies that can be implemented to prevent the onset and progression of overweight and obesity during transitional periods of life\, taking into account physiological\, pathophysiological\, psychological\, and behavioral influences and/or the socioeconomic status of citizens/patients. Importantly\, the proposal should include an assessment of the economic impact of the proposed tools or strategies on the healthcare system and provide recommendations to help policymakers define new regulations and guidelines to prevent overweight and obesity. \n\nSubmission deadline.\nThe following table lists the different dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 13\, 2025\n\n\nDeadline for Pre-Proposals\nJanuary 21\, 2026\, (12:00 CET)\n\n\nNotification of the Results of the Pre-Proposal\nApril 13\, 2026\n\n\nDeadline for full proposals\nJune 11\, 2026\, (12:00 CET)\n\n\nRebuttal Phase\nAugust 24\, 2026\n\n\nProjects begin\nDecember 2026–May 2027\n\n\n\n  \n  URL:https://ibsal.es/en/evento/era4health-partnership-2/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260101 DTEND;VALUE=DATE:20280102 DTSTAMP:20251126T071112Z CREATED:20251126T071112Z LAST-MODIFIED:20251126T071112Z UID:10002178-1767225600-1830383999@ibsal.es SUMMARY:PARTNERSHIP European Partnership for Personalized Medicine (EP PerMed) DESCRIPTION:Features\nA joint transnational call for proposals has been published by the European Partnership for Personalized Medicine (EP PerMed)\, Joint Transnational Call (JTC) 2026: Personalized Medicine for Cardiovascular\, Metabolic\, and Kidney Diseases (CARMEN2026) \nThis call for proposals will fund human health research projects on innovative personalized medicine strategies for patients with cardiovascular\, metabolic\, or kidney diseases. Research projects may focus on a single disease or address these conditions in combination. \nResearch projects that combine a personalized medicine approach with care strategies targeting shared biological pathways or common underlying mechanisms of cardiovascular\, metabolic\, and renal diseases will be viewed favorably. \nThe call for proposals is co-funded by the European Union and involves 39 funding organizations from 27 countries\, with a total estimated budget of over 38 million euros. \nIn addition\, the Carlos III Health Institute (ISCIII) is participating in this call for proposals as the national funding agency. \nRequirements\nProposals should address one or more of the following aspects: \n\nDevelopment and validation of innovative\, personalized therapeutic approaches for cardiovascular\, metabolic\, or kidney diseases through testing in relevant preclinical models (e.g.\, human cell cultures\, organoids\, organs-on-chips\, disease-specific animal models\, or in silico models).\nIdentification and validation of molecular markers/signatures or cutting-edge technologies (see also point 2 below) to monitor treatment response in patients with cardiovascular\, metabolic\, or kidney diseases in order to tailor treatment pathways. This may include the analysis of treatment effectiveness or treatment-related (including those associated with multiple medications) adverse effects\, as well as dose optimization. \nIdentification and validation of stratifying molecular markers or signatures\, or stratifying diagnostic technologies\, for the early prediction of disease risk and the prevention of disease progression or comorbidities in patients with cardiovascular\, metabolic\, or kidney diseases\, thereby delaying the progression to cardiovascular-kidney-metabolic syndrome.\n\n  \nResearch projects that combine a personalized medicine approach with care strategies targeting shared biological pathways or common underlying mechanisms of cardiovascular\, metabolic\, and kidney diseases are welcome. \nProjects funded under this call are also required to include a dedicated work package focusing on the translation or implementation of research outcomes into clinical practice\, with an emphasis on\, for example\, patient outcomes\, patient preferences\, costs\, reimbursement\, education (for healthcare providers\, patients\, and citizens)\, ELSA (ethical\, legal\, and societal aspects)\, or accessibility at the point of care. \nSubmission deadline.\nThe following table lists the different dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 25\, 2025\n\n\nDeadline for Pre-Proposals\nFebruary 10\, 2026\, (2:00 p.m. CET)\n\n\nNotification of the Results of the Pre-Proposal\nMay 5\, 2026\n\n\nDeadline for full proposals\nJune 9\, 2026\, (2:00 p.m. CET)\n\n\nRebuttal stage\nMid- to late August 2026\n\n\nNotification of Funding Decisions\nOctober 2026\n\n\n\n  \n  URL:https://ibsal.es/en/evento/partnership-european-partnership-for-personalized-medicine-ep-permed/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260101 DTEND;VALUE=DATE:20280102 DTSTAMP:20251215T081017Z CREATED:20251215T081017Z LAST-MODIFIED:20251215T081017Z UID:10002206-1767225600-1830383999@ibsal.es SUMMARY:PARTNERSHIP: Transforming Health and Care Systems (THCS) DESCRIPTION:Features\nA joint transnational call for proposals has been published by the Transforming Health and Care Systems (THCS) partnership\, Joint Transnational Call for Proposals (2026) on Access to Care. \nThis call for proposals promotes the coordination and optimization of research and innovation efforts to support the necessary transformation of health and social care systems in Europe and partner countries. Its goal is to fund projects that help ensure equitable access to and appropriate use of health and care services\, providing policymakers and decision-makers with the knowledge and tools needed to reallocate resources effectively. \nThe projects\, based on existing evidence\, will develop innovative solutions to reduce inequalities in access to care by addressing financial models\, service delivery models\, and integrated and interdisciplinary care programs at all levels of the system. \nThe call for proposals is co-financed by the European Union and involves 32 funding organizations\, with a total estimated budget of more than 35 million euros. \nIn addition\, the Carlos III Health Institute (ISCIII) is participating in this call for proposals as the national funding agency. \nRequirements\nThe aim of the call is to fund research and innovation projects that\, within an ecosystem approach\, contribute to ensuring equitable access to and use of health and care services. Through the funded research and innovation projects\, policymakers and decision-makers should gain the knowledge and tools necessary to implement the reallocation of resources as the health and care system undergoes a transition to address new and ongoing challenges. \nAll proposals would benefit from co-creation with stakeholders\, particularly people from disadvantaged groups. Proposals are encouraged to incorporate elements of the social sciences as part of an interdisciplinary approach. \nThis call requires collaborative\, transnational research\, innovation\, and evaluation activities. It is mandatory to engage in one or more of the following types of activities: applied research\, implementation research\, piloting\, upscaling\, and/or testing. All projects must demonstrate proof of concept(s)\, validate concepts\, models\, or solutions\, and showcase demonstrations of solutions in relevant health and care ecosystems. The adaptation of already adopted solutions to other settings is also within the scope of this call. \n  \nSubmission deadline.\nThe following table lists the different dates: \n\n\n\nPhase\nDate\n\n\n\n\nCall Opens\nNovember 21\, 2025\n\n\nDeadline for Pre-Proposals\nFebruary 2\, 2026\, (2:00 p.m. CET)\n\n\nCall for Full Proposals\nStarting May 11\, 2026\n\n\nDeadline for full proposals\nJune 30\, 2026\, (2:00 p.m. CET)\n\n\nRebuttal stage\nSeptember 2026\n\n\nNotification of Funding Decisions\nLate October 2026\n\n\n\n  \n  URL:https://ibsal.es/en/evento/partnership-transforming-health-and-care-systems-thcs/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260101 DTEND;VALUE=DATE:20270101 DTSTAMP:20260112T060813Z CREATED:20260112T060813Z LAST-MODIFIED:20260112T060813Z UID:10002251-1767225600-1798761599@ibsal.es SUMMARY:Reticular Model of Organization and Community Care for People with Mental Illness DESCRIPTION:Coeducational Course: “Reticular Model of Organization and Community Care for People with Mental Illness“ \n  \nObjective: \nTo explain how the network-based model for organizing mental health services and facilities works\, with a focus on the coordination of social and health care services and between mental health and primary care. \n  \nSpecific objectives: \n\nBecome familiar with all the health and social care services integrated into the mental health social-health care network under the network model. Describe the operations and objectives of the Assertive Community Treatment Unit. Conduct a study to develop a feasible proposal for implementation in your workplace.\nTo understand the changes introduced by the model to improve the quality of care in the field of mental health. \nIdentify the epistemological and organizational foundations of the model and its implementation in a healthcare region such as Zamora. \nTo lay the groundwork for coordination among distinct care networks—such as social-health\, social\, and health care networks—as well as to define the new roles of workers within these networks.\n\nDate: \nFrom August 1 to December 31\, 2025. \n  \nLocation: \nOnline and the Zamora Mental Health Department. \n  \nEnrollment: \n  \nRegistration is open throughout the academic year on an individual basis via our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \n  \nPrice: \n50 euros (USAL students\, PhD students\, IBSAL members\, students from developing countries\, primarily in Latin America). \n150 euros (general admission). \n  \nMethod of selection: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n  URL:https://ibsal.es/en/evento/reticular-model-of-organization-and-community-care-for-people-with-mental-illness/ LOCATION:Online\, Online CATEGORIES:Course END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260226 DTEND;VALUE=DATE:20261029 DTSTAMP:20260804T112434Z CREATED:20260601T085642Z LAST-MODIFIED:20260804T112434Z UID:10002348-1772064000-1793231999@ibsal.es SUMMARY:European Innovation Council (EIC) Pathfinder Challenges DESCRIPTION:Features\nThe Commission’s EIC Pathfinder program supports early-stage\, disruptive technological innovations with revolutionary potential. \nFrom the conception of an idea to proof of concept (TRL 1–4)\, the EIC Pathfinder\, as part of the EIC’s Horizon Europe work program\, funds innovative technologies with a transformative impact. It offers two funding options: Open and Challenges\, the latter of which is aimed at specific objectives defined by the EIC and is currently open for applications. \nRequirements:\nThe budget is 96 million euros\, and the topics are: specific challenges of EIC Pathfinder. \nThe following is a list of topics with links: \n\nPathfinder Challenge 1: Advanced Materials for Miniaturized Energy Harvesting Systems: to support the next generation of energy-autonomous systems and IoT devices. Advanced Materials for Miniaturized Energy Harvesting Systems. \nPathfinder Challenge 2: Biotechnology for Healthy Aging: Develop biotechnological or pharmaceutical interventions to prevent\, delay\, or reverse age-related diseases. Biotechnology for Healthy Aging\nPathfinder Challenge 3: DeepRAP: Deep Reasoning\, Abstraction\, and Planning for Trustworthy Cognitive AI Systems: Promoting trustworthy cognitive AI through deep reasoning\, abstraction\, and planning. DeepRAP: Deep Reasoning\, Abstraction & Planning towards trustworthy Cognitive AI Systems\n\n  \nThey are European consortia consisting of at least two entities from different countries or a single legal entity established in a Member State or an associated country. \nEligible applicants include: research organizations and universities\, as well as startups and small and medium-sized enterprises (SMEs) developing high-risk\, high-impact technologies. \nMid- and large-cap companies may not apply as lead applicants. \n  \nProposals are scored (0–5) based on three criteria: \n\nExcellence: ambition\, innovation\, and a high-risk/high-return vision.\nImpact: potential to lay new foundations for innovative technologies.\nImplementation: quality of the consortium and the work plan.\n\n  \nTie-breaking criteria: higher scores for excellence and impact\, gender balance\, and participation by SMEs and countries with the highest participation rates. \nAll essential research-related expenses\, including those for personnel\, equipment\, travel\, and subcontracting\, are covered under the lump-sum grant. \nSubmission Deadline\nThe deadline is October 28\, 2026. URL:https://ibsal.es/en/evento/european-innovation-council-eic-pathfinder-challenges/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260421 DTEND;VALUE=DATE:20270116 DTSTAMP:20260518T124654Z CREATED:20260518T124654Z LAST-MODIFIED:20260518T124654Z UID:10002294-1776729600-1800057599@ibsal.es SUMMARY:Call for Applications: INVESMIR SEC-CNIC Training Program 2026 DESCRIPTION:Purpose\nThe INVESMIR SEC-CNIC Program aims to supplement the training of medical professionals during their hospital residency by facilitating the development of a research project in the CNIC laboratories under the supervision of a CNIC scientist. \nThis program also aims to establish the necessary connections and partnerships so that\, upon completing their specialization\, these professionals can continue to develop their research projects at their respective hospitals\, with the support of the SEC and the CNIC. \n  \nTerms and Conditions\nA maximum of 10 spots will be awarded for the INVESMIR SEC-CNIC training program in the 2026 call for applications. \nThe potential recipient groups for the CNIC under this program and information regarding their research areas are available at the following link:\nhttps://www.cnic.es/es/investigacion/laboratorios \nInterested individuals must contact the research groups and be accepted into one of them in order to apply.\nIn all cases\, the training stints will be full-time. \nParticipants from hospitals outside the Community of Madrid will have their travel expenses to Madrid covered up to a maximum of 300 € (one round-trip from their usual place of residence; if traveling by public transportation\, it must be in economy class\, in accordance with the CNIC’s travel policy). In addition\, these participants will be reimbursed for accommodation expenses in Madrid up to a maximum of 250 euros per week. Any amounts exceeding the weekly limit will be offset against one another\, provided they do not exceed 1\,000.00 € over a four-week period. \nAll expenses must be supported by documentation\, including invoices issued in the participant’s name and proof of payments made from their bank account. The documentation must be sent in a single email to programa_formación@cnic.es within 10 calendar days after the end of the stay at the Center. Once the documentation has been reviewed\, the participant will be notified of which supporting documents must be submitted as original hard copies (invoices\, receipts\, or other supporting documents) and mailed to the Center’s address. \nParticipation in the internship will not entail any type of contractual relationship between the intern and the CNIC. \n  \nDuration and Length of Stay\nThe duration of the stay will be flexible\, ranging from 4 to 6 months\, in accordance with the regulations set forth in the MIR Training Program of the participant’s home hospital.\nStays must take place entirely between June 1\, 2026\, and May 31\, 2027\, except in exceptional circumstances duly authorized by the CNIC and SEC management. \n  \nRequirements\nBe a member of the Spanish Society of Cardiology (SEC).\nBe a medical professional\, of any nationality\, currently in the R3\, R4\, or R5 years of a residency program in Cardiology or Cardiovascular Surgery at a hospital in Spain. \n  \nDeadline and Formalization\nThe call for applications will be open from April 21\, 2026\, through January 15\, 2027.\nApplications must be submitted exclusively through the CNIC online system:\nhttps://www.cnic.es/es/convocatoria/invesmir-sec-cnic\, and the following documentation must be attached: \n\nResume.\nNational Identity Card.\nDocument verifying your personal Social Security number (those issued by mutual insurance companies are not valid).\nA signed authorization from the Academic Committee of the training program at the participant’s home hospital\, expressly stating the dates of the stay.\nLetter of Acceptance from the CNIC Supervising Researcher Responsible for the Stay\nBrief description of the proposed research project for the residency\nCertificate of residence for candidates residing in Spain outside the Community of Madrid.\n\nDocuments must be attached to the form in PDF format. \nFollowing the publication of the call for applications\, applications will be reviewed on the 15th of each month. Each applicant will then be notified by email whether their application has been accepted or\, if applicable\, the reasons for requiring corrections or for exclusion. Applicants in the correction phase may correct the errors that led to the rejection of their application within a maximum period of 5 days\, starting the day after the notification date. The decision regarding admission to or exclusion from the evaluation process will be communicated through the same procedure. \nElectronic signatures will be used throughout the selection process and the subsequent hiring procedures; therefore\, applicants must have a digital ID (DNIe) or a recognized electronic certificate issued by a registered certification authority (https://sedeaplicaciones.minetur.gob.es/Prestadores/)\, such as the one issued by the National Mint and Stamp Factory. \nTERMS AND CONDITIONS OF THE CALL FOR APPLICATIONS URL:https://ibsal.es/en/evento/call-for-applications-invesmir-sec-cnic-training-program-2026/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260501 DTEND;VALUE=DATE:20270101 DTSTAMP:20260518T094535Z CREATED:20260518T094535Z LAST-MODIFIED:20260518T094535Z UID:10002280-1777593600-1798761599@ibsal.es SUMMARY:EATRIS-CONNECCT Knowledge Exchange Program DESCRIPTION:Features\nThe call for applications for the EATRIS-CONNECT knowledge exchange program offers grants of up to €1\,000 for researchers who wish to spend time at an eligible research institution\, with a focus on improving digital transformation in translational medicine. The program covers travel\, lodging\, and living expenses related to the visit. \nDigital transformation in translational medicine refers to the use of advanced digital technologies—such as data\, tools\, and services—to develop innovative solutions to unmet medical needs. \nThe call for applications is open to both EATRIS-CONNECT project partners and EATRIS organizations that are not officially part of the consortium. Expenses will be reimbursed upon completion of the visit and submission of the final report. \nRequirements\nWhat types of exchanges are funded? \nThere are no predefined exchange types\, but some examples include: \n\nDigital Transformation Literacy (DT Literacy): Individual staff exchanges between nodes to facilitate the transfer of knowledge related to digital solutions\, workflows\, and service delivery that support the development of translational medicine.\nWorkshops: group exchange of best practices or collaborative development of digital solutions.\nCollaborative initiatives: sharing experiences and ideas to drive joint digital transformation initiatives.\nOnline or virtual knowledge-sharing sessions: digital seminars\, webinars\, and other virtual events for sharing knowledge.\n\n\n\n\nHow to apply\nYou must submit the “Knowledge Exchange proposal” via this link to the application form. Before submitting it\, please verify your eligibility\, and we recommend that you read the program guide. \nThere is no deadline for submitting applications. URL:https://ibsal.es/en/evento/eatris-connecct-knowledge-exchange-program/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260701 DTEND;VALUE=DATE:20261009 DTSTAMP:20260903T122819Z CREATED:20260903T122819Z LAST-MODIFIED:20260903T122819Z UID:10002385-1782864000-1791503999@ibsal.es SUMMARY:American Society of Clinical Oncology\, Career Development Award DESCRIPTION:Features\nThe American Society of Clinical Oncology (ASCO) awards its Career Development Awards (CDA)\, which provide research funding to clinical investigators who have received their first faculty appointment as they work to establish an independent clinical cancer research program. \nThis is a mentored award\, and the research project is conducted under the guidance of a scientific mentor. The research must have a patient-oriented focus\, including a clinical research study and/or translational research involving human subjects. Proposals that focus primarily on in vitro or animal studies (even if clinically relevant) are not permitted. \nApplications in all areas of cancer research are accepted from U.S. and international applicants. \nThe grant period runs from July 1\, 2027\, through July 1\, 2030. The funding budget is $66\,600 per year. \nRequirements:\n\nApplicants must be physicians (MD\, DO\, or international equivalent).\nAt the time of submission\, applicants must be in their first through fourth year of their initial full-time faculty appointment in a clinical department at an academic medical institution. Eligible entry-level positions may include Instructor/Lecturer\, Assistant Professor\, or Assistant Member. \nApplicants must hold a valid\, active medical license in the country where the research will be conducted for the entire duration of the grant.\nApplicants must have completed productive postdoctoral research and demonstrated the ability to conduct independent\, investigator-initiated clinical research.\nApplicants must be current ASCO members or have submitted a membership application along with their grant application.\nApplicants must be able to devote at least 50% of their time to research during the grant period. This applies to their total research activity\, not just to the proposed project. \nApplicants must have a mentor from the sponsoring institution. If the mentor is not an ASCO member\, the application must include a letter of support from an ASCO member at the sponsoring institution. \nApplicants who hold other career development awards or institutional training grants may apply\, provided there is no scientific or budgetary overlap.\nApplicants should not have previously served as Principal Investigator on a major project grant\, such as an R01 or its international equivalent.\n\nHow to apply\nThe application must be submitted online through the ASCO Application Portal and must follow the instructions set forth in the Request for Proposals (RFP). \nThe deadline is October 8\, 2026. URL:https://ibsal.es/en/evento/american-society-of-clinical-oncology-career-development-award/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260716 DTEND;VALUE=DATE:20261116 DTSTAMP:20260717T081311Z CREATED:20260717T081311Z LAST-MODIFIED:20260717T081311Z UID:10002266-1784160000-1794787199@ibsal.es SUMMARY:“Salamanca Institute of Biomedical Research – Royal Academy of Medicine” Award DESCRIPTION:Description\nThe “Salamanca Biomedical Research Institute – Royal Academy of Medicine” Award for the best innovative work in health sciences conducted in 2026 by medical and non-medical professionals affiliated with the Salamanca Biomedical Research Institute (IBSAL). \n\n\n\n  \nAward\nThe prize consists of €1\,000 and a certificate. \n  \nPresentation\nTo submit an entry\, the candidate for the award must send the work and the relevant documentation (CVN and 3 copies of the work\, along with an electronic copy. In the case of multiple authors\, informed consent from all authors must be provided for the submission of the work to the award) for evaluation\, along with detailed information on the project’s current status. \nThe documents should be sent to the Academy’s email address\, ramsa@usal.es. \nThe documentation must be submitted by 1:00 p.m. on November 15\, 2026. \n  \nEvaluation\nThe judging panel\, composed of four Full Members of the RAMSA\, will issue its final evaluation based on the following criteria: the originality of the innovation—which may be basic\, clinical\, educational\, managerial\, etc.; its impact; other aspects that the committee deems relevant regarding the merits demonstrated by the author\, provided that they are related to the innovation. \n  \nRead the rules URL:https://ibsal.es/en/evento/salamanca-institute-of-biomedical-research-royal-academy-of-medicine-award/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260803 DTEND;VALUE=DATE:20261106 DTSTAMP:20260903T093329Z CREATED:20260903T090320Z LAST-MODIFIED:20260903T093329Z UID:10002378-1785715200-1793923199@ibsal.es SUMMARY:BREAKTHROUGH T1D\, Type 1 Diabetes Research DESCRIPTION:Features\n  \nThe Breakthrough T1D organization is now accepting applications for project concepts. This is a semi-annual call for Letters of Intent for Strategic Research Agreements that address Breakthrough T1D’s current research strategy. \nThis call supports individual and collaborative projects that address critical gaps and challenges in type 1 diabetes research. \nRequirements:\n\nProposals may be submitted by nonprofit or public organizations. Generally\, for-profit organizations will not be considered\, except under special circumstances. \nApplicants must hold an MD\, DMD\, DVM\, DO\, PhD\, or equivalent degree and hold a faculty position or equivalent at a college\, university\, medical school\, company\, or other research facility.\n\nHow to apply\nThe application process consists of two steps. Letters of Intent (LOIs) must be submitted through the RMS360 portal. Letters of Intent and full proposals are due by 5:00 p.m. Eastern Time on the following deadline dates: \nRound 1: \nLetters of Intent due November 5\, 2026 (link) \nNotification by December 17\, 2026 \nRound 2: \nLetters of Intent are due on May 6\, 2027 \nNotification by URL:https://ibsal.es/en/evento/breakthrough-t1d-type-1-diabetes-research/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261103 DTSTAMP:20260903T110132Z CREATED:20260903T110132Z LAST-MODIFIED:20260903T110132Z UID:10002386-1788220800-1793663999@ibsal.es SUMMARY:EASD Albert Renold Travel Fellowship Program DESCRIPTION:Features\nThe EASD Albert Renold Travel Fellowships enable scientists and clinicians to travel and stay at other institutions in order to learn specific techniques or clinical skills required for the advancement of their diabetes research project and not available at their home institution. \nThe home institution and/or the host institution must be based in Europe or a country associated with Europe (for a detailed list of countries\, please see here); both must be nonprofit organizations\, and each must be located in a different country. Applicants must be employed at their home institution during the term of the award. \nThe duration of the stay may be up to 3 months. The requested amount for each fellowship may be up to 10\,000 euros. \nRequirements:\n\nApplicants must be early-career scientists or clinicians who\, as of January 1 of the year the fellowship is awarded\, have completed their most recent degree (PhD\, MSc\, or MD) within the past 7 years. Eligibility may be extended for duly justified career breaks. Fellows may not hold a permanent appointment. \nThe home and/or host institution must be based in Europe or a country associated with Europe; both must be nonprofit organizations\, and each must be located in a different country. Applicants must be employed at their home institution during the duration of the grant. \nSuccessful applicants must travel within nine months of receiving the award.\nFunds cannot be used to help pay for part of a longer stay.\nAwardees may not receive a second fellowship within two years of receiving their award.\nApplicants must be members of the EASD in good standing.\n\nHow to apply\nApplications must be submitted through the EFSD portal by 12:00 p.m. (CET) on the deadline\, November 2\, 2026. URL:https://ibsal.es/en/evento/easd-albert-renold-travel-fellowship-program-2/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260901 DTEND;VALUE=DATE:20261117 DTSTAMP:20260903T112956Z CREATED:20260903T112956Z LAST-MODIFIED:20260903T112956Z UID:10002387-1788220800-1794873599@ibsal.es SUMMARY:German Academic Exchange Service (DAAD) Binationally Supervised Doctoral Degrees / Cotutelle DESCRIPTION:Features\nThe Deutscher Akademischer Austauschdienst (DAAD) / German Academic Exchange Service offers the“Bi-nationally Supervised Doctoral Degrees / Cotutelle” program. This program provides doctoral candidates with the opportunity to pursue a bi-national doctoral degree at their home university and at a university in Germany. \nThere are two types of doctoral programs: \n\nOption a) Doctorate with binational supervision (“sandwich model”): The PhD project is supervised jointly by an academic advisor at the home university and another at the host institution in Germany. The doctoral degree is awarded by the home university. \nOption b) Joint Doctoral Program: The PhD project is carried out jointly at the home university and a university in Germany under an individual joint supervision agreement established specifically for the project. Upon successful completion\, the two universities jointly award the doctoral degree. \n\n  \nThe scholarship provides €1\,400 per month for the research stay in Germany\, for a period of 7 to 24 months. \nIt also includes a travel allowance\, a €460 research allowance\, and health\, accident\, and liability insurance. Additional allowances may be available depending on the applicant’s circumstances. \nRequirements:\n\nAs a general rule\, the most recent university degree must have been earned no more than 6 years prior to the application deadline.\nIf the doctoral program has already begun\, it must have started no more than 3 years before the application deadline.\nApplicants must not have been residents of Germany for more than 15 months as of the application deadline.\nFor the “Sandwich Model\,” applicants must hold a master’s degree or a Diplom (or\, in exceptional cases\, a bachelor’s degree) by the start of the funding period.\nFor the “Cotutelle model\,” applicants must have been admitted to a doctoral program by the start of the funding period.\n\n\nHow to apply\nApplications must be submitted online via the DAAD Portal—by clicking the “SUBMIT AN APPLICATION” button. Applicants must complete the online application form and upload the required supporting documents\, including the research proposal\, CV\, motivation letter\, academic documents\, and the confirmation from the German supervisor. \nFor the Cotutelle option\, an individual Cotutelle agreement between the home university and the German university is required before the funding period begins. The application deadline is November 16\, 2026. URL:https://ibsal.es/en/evento/german-academic-exchange-service-daad-binationally-supervised-doctoral-degrees-cotutelle-2/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260907 DTEND;VALUE=DATE:20261107 DTSTAMP:20260903T084350Z CREATED:20260903T082838Z LAST-MODIFIED:20260903T084350Z UID:10002376-1788739200-1794009599@ibsal.es SUMMARY:Sarcoma Foundation of America (SFA) Research Grants DESCRIPTION:Features\nThe Sarcoma Foundation of America Research Grants support researchers conducting preclinical\, translational\, and clinical research on the etiology\, molecular biology\, pathogenesis\, diagnosis\, and treatment of human sarcomas. This program supports research and promotes awareness and advocacy for sarcoma patients and their families. The goal of the SFA grant program is to support research that leads to improved treatment options for sarcoma patients. The SFA encourages applications from ALL areas of sarcoma research. \nThe total award amount is $75\,000 for one year. The grants are awarded on an annual basis from July 1\, 2027\, to June 30\, 2028. SFA encourages applications in ALL areas of sarcoma research from U.S. and international applicants. \nRequirements:\n\nApplicants must hold an MD\, DO\, PhD\, or international equivalent—whether in the U.S. or abroad—and possess the skills\, knowledge\, and resources necessary to carry out the proposed sarcoma research;\nOnly one applicant may be designated as the principal investigator (PI) for each grant. The PI is responsible for the overall management\, coordination\, and oversight of the research\, including all deliverables; \nApplications from researchers outside the U.S. must be able to provide a budget and accept funds in U.S. dollars;\nReturning SFA principal investigators and organizational grantees must comply with all previous SFA grant deliverables\n\nHow to apply\nThe SFA Research Grant Program is a two-stage process. All applicants must submit a Letter of Intent (LOI). Only the highest-ranked LOIs will be invited to submit full applications. \nThe deadline for submitting the Letter of Intent is November 6\, 2026\, at 11:59 p.m. EST. The link to Proposal Central for Applicants & Awardees. URL:https://ibsal.es/en/evento/sarcoma-foundation-of-america-sfa-research-grants/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260909 DTEND;VALUE=DATE:20261117 DTSTAMP:20260909T115154Z CREATED:20260909T115154Z LAST-MODIFIED:20260909T115154Z UID:10002380-1788912000-1794873599@ibsal.es SUMMARY:DKMS John Hansen Research Grant 2026 DESCRIPTION:Features\nThe DKMS John Hansen Research Grant provides funding for research into hematopoietic stem cell transplantation and cell therapy for hematological diseases. The application period for the 2027 grant is now open. \nThe DKMS John Hansen Research Grant supports promising young scientists conducting research in the field of blood cancer\, with a particular focus on hematopoietic stem cell transplantation and cell therapy for hematological diseases. Projects primarily focused on product development\, commercialization\, or other commercial activities are not eligible. \nThe grant may cover\, among other things\, consumables\, the principal investigator’s (PI) own position\, a Ph.D. student dedicated to the project\, technicians who devote at least 30% of their time to the project\, relevant training\, and certain publication costs. Up to EUR 2\,500 per year can be used for travel\, lodging\, and registration fees for a scientific conference to present project results\, and up to EUR 10\,000 may be allocated for reasonable publication costs\, including open-access fees. \nThe grant lasts up to 3 years. Each annual funding period runs from July 1 to June 30 of the following year. The funding amounts to up to EUR 240\,000\, with a maximum of EUR 80\,000 per year. \nRequirements:\n\nApplicants from all countries are welcome to apply.\nApplicants must have earned a doctoral degree (PhD\, MD\, or equivalent) in a field relevant to the grant within the 10 years preceding the start of the call for proposals.\nApplicants must appoint a supervisor\, ideally a senior scientist at the host institution with expertise relevant to the proposed research.\n\nHow to apply\nApplicants must submit: \n\ninformation about the applicant;\na description of the research project; and\na budget plan\, following the application instructions.\n\nApplications must be submitted via email to grant@dkms.org by November 16\, 2026\, at 11:59 p.m. (Central European Time). URL:https://ibsal.es/en/evento/dkms-john-hansen-research-grant-2026/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;TZID=Europe/Helsinki:20260910T000000 DTEND;TZID=Europe/Helsinki:20261009T140000 DTSTAMP:20260920T124333Z CREATED:20260920T124056Z LAST-MODIFIED:20260920T124333Z UID:10002415-1788998400-1791554400@ibsal.es SUMMARY:Call for Proposals: 9th Social and Health Research Grant Program - Caser Foundation DESCRIPTION:Purpose\nThe purpose of this call for proposals is to provide financial support\, through the signing of a collaboration agreement\, for social and health research projects that can be effectively carried out within one year. \nThe research projects submitted must pertain to the social and health care sector and address topics such as dependency\, integrated care\, and person-centered care\, with priority given to innovative projects that enhance well-being and are easily replicable and transferable. \n  \nTypes of Projects\nTo achieve these objectives\, the Caser Foundation will use this call for proposals to support research related to the following stakeholder groups: \n• People who are dependent on others. \n• People receiving palliative care. \n• People with disabilities. \n• Older adults. \n• Informal caregivers for the individuals mentioned above. \nProposals may be submitted in the field of research in any of the following areas: • Integrated care. • Social and health care coordination. \n• Promoting personal autonomy. \n• Technology applied to social and health care integration. \n• Improving quality of life as people age. \n• Social inclusion \nProjects focused exclusively on the health or social sector will not be accepted; rather\, projects that integrate both sectors—within the themes and target groups specified in these guidelines—and that are always aimed at the inclusion and well-being of the intended beneficiaries will be accepted. \n  \nScope of Activities and Applicant Requirements\nThis call for proposals is open nationwide; that is\, researchers must reside in Spain\, and the research must also be conducted in Spain. \nParticipation in this call for proposals is open to any team of individuals working at public or private research centers\, including universities\, NGOs\, foundations\, companies\, or any other organization specifically dedicated to research. The collaboration agreement will ultimately be signed with the legal entity. \nThe applicant must commit to a stable involvement in the project for its entire duration\, until its successful completion. There are no restrictions on applicants for reasons unrelated to the very nature of this grant. \n  \nCharacteristics of the Grants\nDepending on the characteristics of the projects to be funded\, the grants provided by the Foundation will have the following specifications:\n1. The activities must be carried out within one year of the signing of the collaboration agreement. \n2. Each applying team may participate in only one project. \n3. Selected projects may receive funding ranging from a minimum of 5\,000 euros to a maximum of 20\,000 euros over the course of one year. The funds awarded must be used entirely for the implementation of the project; the project’s objectives\, methodology\, and anticipated expenses must be clearly specified and\, upon request by the Caser Foundation\, documented at any time and\, in any case\, upon completion of the project. \n4. Grants awarded under this call for proposals are subject to the tax regulations currently in effect in Spain \n  \nDeadline and Submission of Applications\nThe application period will begin on September 10\, 2026\, and end on October 9\, 2026\, at 2:00 p.m. Applications must be submitted using the form provided for this purpose at the following link: https://www.fundacioncaser.org/investigacionsociosanitaria \nYou must attach the following required documentation to this form: \n• Project proposal using the template provided in the form attached as Annex I to this call for proposals\, with a maximum length of 4\,000 words. The proposal must include the following information: description\, objectives and/or hypotheses\, methodology\, timeline\, direct and indirect beneficiaries\, expected results\, budget\, and project team\, including a detailed description of each member’s role in the project’s implementation.\n• A summary of no more than 300 words\, indicating: the purpose\, innovative nature\, and social and health-related relevance of the project\, as well as its alignment with the interests of the foundation and this call for proposals.\n• CVs of the applicant researcher\, as well as those of the other researchers who plan to be involved in the project. All applications must include a research team that is consistent with the project’s objectives\, methodology\, tasks\, and expected results. \n  \nFULL TERMS AND CONDITIONS of the Call for Applications URL:https://ibsal.es/en/evento/call-for-proposals-9th-social-and-health-research-grant-program-caser-foundation/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260914 DTEND;VALUE=DATE:20261023 DTSTAMP:20260916T210510Z CREATED:20260916T210127Z LAST-MODIFIED:20260916T210510Z UID:10002408-1789344000-1792713599@ibsal.es SUMMARY:Call for Applications: Pasqual Maragall Researchers Program DESCRIPTION:Description and Objective\nThe Scholarship Program Pasqual Maragall Researchers Program (PMRP) funds outstanding research projects on Alzheimer’s disease and other age-related neurodegenerative diseases. \nThe objectives are to promote and support translational or clinical research projects on Alzheimer’s disease or other age-related neurodegenerative diseases. The PMRP will provide funding of up to 800\,000 € for individual or collaborative research projects to be carried out over a maximum period of five years. \n\nApplications\nPrincipal investigators of individual research projects or coordinators of collaborative research project consortia must hold a position as an independent researcher at a public or nonprofit research organization in Spain. \nIn the case of collaborative research projects\, the other members of the consortium (principal investigators in the consortium) may be affiliated with a public or nonprofit research organization anywhere in the world. \nWe recommend reviewing the “Rules for Participation” document to learn about the eligibility criteria. \n\nEligibility Criteria\nThe application process for grants under the Pasqual Maragall Researchers Program (PMRP) consists of two phases: \n\nPhase 1: Submission of an Expression of Interest (EOI).\nPhase 2: Submission of a complete proposal\, by invitation only.\n\nThe entire project application\, review\, and selection process will be conducted in English; therefore\, all information must be submitted in that language. Applications must be submitted via this link. Please read the “Submission Guidelines” document carefully before beginning the application. \n\nCall for Applications Timeline\nThe key dates for the 2026 call for applications for the Pasqual Maragall Researchers Program (PMRP) are: \n\nSeptember 14\, 2026\, 10:00 a.m. CEST: Opening of the application system for submitting the EI.\nOctober 22\, 2026\, 3:00 p.m. CEST: Deadline for submitting the EI.\nFebruary 2027: Announcement of the results of the call for proposals and invitation to submit full proposals.\nApril 2027: Deadline for submitting the complete proposal (by invitation only).\nJuly 2027: Notification of the results of the complete proposals to the applicants.\nTo be confirmed: public announcement of the results.\n\n*Dates are subject to change. Applicants will be notified of any relevant changes. \n\nSelection Process\nThe review process for both the EI and the full proposals consists of three phases: administrative review\, scientific review\, and strategic review. \n\nThe Strategic Research Funding team conducts an administrative review to ensure that only complete applications that meet all eligibility criteria are evaluated by the Evaluation Committee and the Selection Committee.\nThe Evaluation Committee is composed of experts of internationally recognized standing in their respective fields. Its role is to evaluate and score the applications in accordance with the call for proposals’ evaluation criteria (detailed in the document“Evaluation Procedure”) and to report the results of the evaluation to the Selection Committee. \nIn addition to the evaluation criteria\, the Selection Committee of the Pasqual Maragall Researchers Program (PMRP) assesses how well the proposals align with the Pasqual Maragall Foundation’s strategic plan and the PMRP’s priorities. Members of the Selection Committee may include the Foundation’s director\, management consultants\, faculty members\, and members of the Scientific Advisory Committee of the Foundation’s research center\, as well as experts of recognized international standing in their fields. \n\nExpressions of interest that receive the most favorable evaluation will be invited to submit a full proposal. \nThe proposals that receive the most favorable evaluations will be invited to sign a grant agreement with the Pasqual Maragall Foundation. \nIn the document“Evaluation Procedure\,” you will find more detailed information about the criteria and the review process for the proposals received. \nCALL FOR ENTRIES WEBSITE URL:https://ibsal.es/en/evento/call-for-applications-pasqual-maragall-researchers-program/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20260921 DTEND;VALUE=DATE:20261231 DTSTAMP:20261002T082542Z CREATED:20261002T082542Z LAST-MODIFIED:20261002T082542Z UID:10002428-1789948800-1798675199@ibsal.es SUMMARY:Scientific and Technical Sessions for Senior Clinical and Biomedical Diagnostic Technicians DESCRIPTION:Scientific and Technical Sessions for Senior Clinical and Biomedical Diagnostic Technicians \n  \nObjective: \nTo update knowledge on diagnostic procedures\, quality control\, and new laboratory tools. \n  \nSpecific objectives: \nTo analyze the quality control procedures applied to hematopoietic progenitor cells in the context of allogeneic transplantation. \nTo determine the diagnostic utility and clinical application of the GFAP and UCH-L1 biomarkers in patients with mild acute brain injury. \nTo evaluate the utility of automated hematology systems and their correlation with conventional morphological methods. \n  \nDate: \nStart Date: September 21\, 2026 \nEnd: December 30\, 2026 \n  \nLocation: \nCAUSA DP0518 Auditorium \nProgram: \n\n\n\nDate / Time\nLocation\nSpeaker\nContent\n\n\nSeptember 21\, 26\nCAUSA DP0518 AUDITORIUM\n– María Magdalena Barbero García\n– CORRELATION BETWEEN HEMOGLOBIN LEVELS MEASURED BY THE GEM 5000 WERFEN BLOOD GAS ANALYZER AND THE SIEMENS ADVIA 2120I CYTOMETER\n\n\n13:30 / 15:30\n\n\n10/26/19\nCAUSA DP0518 AUDITORIUM\n– REBECA ORTEGA HERRERA\n– QUALITY CONTROL OF HEMATOPOIETIC PROGENITOR CELLS USING CLONOGENIC ASSAYS IN THE CONTEXT OF ALLOGENEIC TRANSPLANTATION. \nFUNCTIONAL COMPARISON OF FRESH VERSUS CRYOPRESERVED PROGENITOR CELLS\n\n\n13:30 / 15:30\n\n\n11/23/26\nCAUSA DP0518 AUDITORIUM\n– SOFIA GONZALEZ MARTIN\n– DETERMINATION OF BIOMARKERS FOR MILD ACUTE BRAIN INJURY IN THE EMERGENCY ROOM LABORATORY: GFAP AND UCH-L1\n\n\n13:30 / 15:30\n\n\n12/14/26\nCAUSA DP0518 AUDITORIUM\n– MARIA DE LOS ANGELES GOMEZ GONZALEZ\n– CORRELATION BETWEEN THE ADVIA 2120 AUTOMATED LEUKOCYTE DIFFERENTIAL COUNT AND THE MORPHOLOGICAL COUNT ASSISTED BY CELIAVISION\n\n\n13:30 / 15:30\n\n\n\nEnrollment: \nREGISTRATION: \nIndividually\, through our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \nSeats: \n30 for IBSAL staff \nMethod of selection: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n  URL:https://ibsal.es/en/evento/scientific-and-technical-sessions-for-senior-clinical-and-biomedical-diagnostic-technicians/ LOCATION:Hospital Clínico. Complejo Asistencial Universitario de Salamanca (Salamanca University Welfare Complex)\, Pº de San Vicente\, 182\, Salamanca\, Salamanca\, Spain CATEGORIES:Sacyl Course END:VEVENT BEGIN:VEVENT DTSTART;TZID=UTC:20260924T081500 DTEND;TZID=UTC:20261210T094500 DTSTAMP:20260901T110351Z CREATED:20260831T120427Z LAST-MODIFIED:20260901T110351Z UID:10002361-1790237700-1796895900@ibsal.es SUMMARY:2nd Edition of the Continuing Education Program on Inflammatory Nasal and Sinus Diseases in Castile and León DESCRIPTION:“Second Edition of the Continuing Education Program on Inflammatory Nasal and Sinus Diseases in Castile and León” \n  \nObjective: \n\n\n\nTo determine therapeutic management and experience in treating patients with severe chronic non-polypoid sinusitis (CNPS). \nTo establish criteria for the indication and treatment of various nasosinusal conditions (epistaxis\, septopyramidal deviation\, eosinophilic otitis).\n\n\n\n  \nSpecific objectives: \n  \n\n\n\n-Establish a treatment strategy\, incorporating biologics into the current treatment algorithm. \n-Evaluation of real-world outcomes of treatment with biologic drugs. \n-Establish a standardized approach to the management of epistaxis in the emergency department. \n-Establish the criteria for surgical indication and the surgical techniques for patients with septopyramidal deviation.\n\n\n\n  \nLocation: \nTEAMS link. \n  \nProgram: \n\n\n\nCourse Date\nSchedule\nContent\nSPEAKER \n\n\n Thursday\, September 24\, 2026\n8.15-9.45\n  \n‘s Septorhinoplasty Online \n \nMs. María Gil Melcón \nHead of the Otolaryngology Section. CAUSA \n\n\n Thursday\, November 5\, 26\n8.15-9.45\n  \nEosinophilic Otitis: Diagnosis\, Treatment\, and Outcomes in CAUSA \nOnline \n \nMs. Susana Marcos Alonso \nL.E.A. Otolaryngology. CAUSE \n\n\n Thursday\, December 10\, 2026\n8.15-9.45\nDupilumab in Real-World Practice in CAUSA \nOnline.\nMr. Juan Carlos del Pozo de Dios \nL.E.A. Otolaryngology. CAUSE. \n\n\n\n  \nEnrollment: \nREGISTRATION: \nThe registration deadline is Tuesday\, September 22\, 2026; you must register individually through our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \n  \nMethod of selection: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n  URL:https://ibsal.es/en/evento/2nd-edition-of-the-continuing-education-program-on-inflammatory-nasal-and-sinus-diseases_castile-and-leon/ CATEGORIES:Course ATTACH;FMTTYPE=image/png:https://ibsal.es/wp-content/uploads/2026/08/Regeneron-logo--scaled.png END:VEVENT BEGIN:VEVENT DTSTART;TZID=UTC:20261001T081500 DTEND;TZID=UTC:20261127T094500 DTSTAMP:20260902T075759Z CREATED:20260901T105743Z LAST-MODIFIED:20260902T075759Z UID:10002363-1790842500-1795772700@ibsal.es SUMMARY:2nd Edition of the Continuing Education Program on Inflammatory Nasal and Sinus Pathology in Salamanca DESCRIPTION:“2nd Edition of the Continuing Education Program on Inflammatory Nasal and Sinus Diseases in Salamanca” \n  \nObjective: \n\n\n\nTo determine therapeutic management and experience in treating patients with severe chronic non-polypoid sinusitis (CNPS). \nTo establish criteria for the indication and treatment of various nasosinusal conditions (epistaxis\, septopyramidal deviation\, eosinophilic otitis). \n \n\n\n\n  \nSpecific objectives: \n  \n\n\n\n-Establish a treatment strategy\, incorporating biologics into the current treatment algorithm. \n-Evaluation of real-world outcomes of treatment with biologic drugs. \n-Establish a standardized approach to the management of epistaxis in the emergency department. \n-Establish the criteria for surgical indication and the surgical techniques for patients with septopyramidal deviation. \n \n\n\n\n  \nDate: October 1\, 2026\, through November 26\, 2026 \n  \nLocation: \nLibrary of the Otolaryngology Department at the University Hospital of Salamanca. \n  \nProgram: \n\n\n\nCourse Date\nSchedule\nContent\nSpeaker\n\n\nThursday\, \n\, October 1\, 26\n8.15-9.45\nMultiple-choice case studies of patients with cPN-CSC treated with biologic drugs. \nIn-person\nMs. Susana Marcos Alonso \nL.E.A. Otolaryngology. CAUSE \n\n\nThursday\, \n\, October 22\, 2026\n8.15-9.45\nEpistaxis: Therapeutic Management. \nIn-person\nMs. María Gil Mencón \nHead of the Otolaryngology Section. CAUSA \n\n\nThursday\, November 26\, \n\n8.15-9.45\nComprehensive Treatment of cPN-CSR: Surgery and Biologics. \nIn-Person\nMr. Fernando Franco Calvo \nHead of the Otolaryngology Department. CAUSA \n\n\n\nEnrollment: \nREGISTRATION: \nThe registration deadline is Friday\, September 29\, 2026; please register individually through our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \n  \n  \nMethod of selection: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n  URL:https://ibsal.es/en/evento/2nd-edition-of-the-continuing-education-program-on-inflammatory-nasal-and-sinus-diseases-salamanca/ LOCATION:Otolaryngology Department.\, Library of the Otolaryngology Department at the University Hospital of Salamanca CATEGORIES:Course ATTACH;FMTTYPE=image/png:https://ibsal.es/wp-content/uploads/2026/08/Regeneron-logo--scaled.png END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20261005 DTEND;VALUE=DATE:20261107 DTSTAMP:20260917T123727Z CREATED:20260917T120713Z LAST-MODIFIED:20260917T123727Z UID:10002409-1791158400-1794009599@ibsal.es SUMMARY:An Overview of the Donation and Transplant Process DESCRIPTION:Online course: \nAn Overview of the Donation and Transplant Process. \nObjective: \nTo raise awareness and improve healthcare workers’ knowledge of the donation and transplantation process. \nSpecific objectives: \nImproving the identification of potential donors at the facilities of the Salamanca Healthcare Complex \nDissemination of the Maastricht III protocol and procedure for donation in cases of asystole. \nUpdates on the care and support of potential donors. Improving healthcare staff’s skills in interacting with the donor’s family. \nDATE: \nOctober 5 through November 6\, 2026 \nLocation: \nIBSAL Moodle Platform \nProgram: \nMonday\, October 5\, 2026 \n\n4:00 p.m. – 4:20 p.m. | Course Introduction (M.A. Bravo)\n4:30 p.m. – 5:00 p.m. | The Donation Process: Medical Records (V. Sagredo)\n5:00 p.m. – 5:30 p.m. | Donation Process: Nursing Perspective (M.A. Bravo)\n5:30 p.m. – 6:00 p.m. | Brain Death: Clinical Aspects (M. Gutiérrez)\n6:00 p.m. – 6:30 p.m. | Brain Death: Instrumental Diagnosis (S. Muñoz)\n\nTuesday\, October 6\, 2026 \n\n4:00 p.m. – 4:30 p.m. | Clinical evaluation of the donor (M. Bueno)\n4:30 p.m. – 5:00 p.m. | Donor Care (I. Fernández)\n5:00 p.m. – 5:30 p.m. | Nursing Care for Donors (J.C. Martín)\n5:30 p.m. – 6:10 p.m. | Maastricht III Asystole Donor (Á. García)\n\nWednesday\, October 14\, 2026 \n\n3:55 p.m. – 4:00 p.m. | Module II Presentation (M.A. Bravo)\n4:00 p.m. – 6:00 p.m. | Legal Issues and Clinical Documentation (M.D. Calvo)\n6:00 p.m. – 8:00 p.m. | Family and Donation (Fr. Rojo)\n\nWednesday\, October 21\, 2026 \n\n3:55 p.m. – 4:00 p.m. | Presentation: Module III (M.A. Bravo)\n4:00 p.m. – 4:30 p.m. | Maastricht III Donation After Cardiac Death (M.A. Bravo)\n4:30 p.m. – 5:00 p.m. | Transplant Immunology (A. Tejeda)\n5:00 p.m. – 6:00 p.m. | Liver Removal and Transplantation (C. Esteban\, M.J. Iglesias)\n6:00 p.m. – 6:30 p.m. | Pancreas Transplant (J. López)\n6:30 p.m. – 7:00 p.m. | Kidney Retrieval and Transplantation Techniques (Ó. Heredero\, J. Salvatierra)\n7:00 p.m. – 7:30 p.m. | Kidney Transplantation from a Living Donor (P. Eguiluz\, A. Martín)\n7:30 p.m. – 8:00 p.m. | Robotic and Complex Kidney Transplants (A. Palacios\, C. Sánchez)\n\nTuesday\, October 27\, 2026 \n\n3:55 p.m. – 4:00 p.m. | Presentation: Module IV (M.A. Bravo)\n4:00 p.m. – 4:30 p.m. | The Eyeball and Corneal Implants (G. Rodríguez)\n4:30 p.m. – 5:00 p.m. | Osteotendinous tissue (S. Serrano)\n5:00 p.m. – 5:30 p.m. | Bone Marrow Transplant (L. López)\n5:30 p.m. – 6:00 p.m. | Follow-up Care for Kidney Transplant Patients (G. Tabernero)\n6:00 p.m. – 6:30 p.m. | Postoperative Care for Pancreas and Kidney Surgery (M. González)\n6:30 p.m. – 7:30 p.m. | Roundtable Discussion: Patient Organizations and Patient Experiences (M.A. Bravo\, A. Rivero)\n7:30 p.m. – 8:00 p.m. | The Present and Future of Organ Donation and Transplantation (M.A. Bravo\, V. Sagredo)\n\n  \nSeats: \n5 for IBSAL staff \nEnrollment: \nREGISTRATION: \nNote: HUS staff who are not affiliated with IBSAL must register through the GESTION@FC training application: www.salud.jcyl.es/gestio@fc \nThe pre-registration period for IBSAL staff runs through Friday\, October 1\, via our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \nPlease note that you can only be considered registered for the course when you receive the confirmation email\, as there is a limit to the number of places available. \nSELECTION METHOD: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n  \n  \n  \nIBSAL TRAINING URL:https://ibsal.es/en/evento/an-overview-of-the-donation-and-transplant-process/ CATEGORIES:Sacyl Course END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20261008 DTEND;VALUE=DATE:20261111 DTSTAMP:20260930T114159Z CREATED:20260921T083446Z LAST-MODIFIED:20260930T114159Z UID:10002417-1791417600-1794355199@ibsal.es SUMMARY:Mental Health in People with Intellectual Disabilities: Assessment and Intervention. DESCRIPTION:In-person/online course: \nMental Health in People with Intellectual Disabilities: Assessment and Intervention. \nObjective: \nIdentify and understand intervention methods for behavioral and/or psychiatric disorders in people with intellectual disabilities. \nSpecific objectives: \n\nAddressing Mental Health Issues (Primarily Behavioral and Psychiatric Disorders) Among People with Intellectual Disabilities: Current Situation and Needs.\n\n  \n\nIdentify and understand the main behavioral and psychiatric issues faced by people with intellectual disabilities.\n\n  \n\nLearn the assessment and diagnostic methodology for people with intellectual disabilities who have mental health issues.\n\n  \n\nTo understand intervention methodologies for people with intellectual disabilities who exhibit behavioral and psychiatric disorders\n\n  \n\nReview the principles of pharmacological treatment for people with intellectual disabilities and mental health issues. And establish the best strategies for pharmacological intervention. \n\n  \n\nTo learn about and evaluate the different models of care for people with intellectual disabilities and mental health issues\, with a particular focus on Castile and León\, as well as to learn about the resources available in Castile and León and how to access them.\n\n  \n\nTo evaluate the best intervention methodology for improving the care and treatment of psychiatric and behavioral problems in people with intellectual disabilities.\n\n  \n  \nDATE: \nOctober 8\, 2026\, and November 10\, 2026 \nLocation: \nZamora Healthcare Complex—Virgen de la Concha Hospital // Online \nProgram: \n\n\n\nDate of delivery\nSchedule\nContent\nTeacher and Qualification\n\n\n8/10/2026\n9:30-10:00\nCourse introduction and teaching methodology. Relevance of the topic. \nManuel A. Franco Martín. \nPsychiatrist. Chief of the Department of Psychiatry and Mental Health at CAZA (ID No.: 09278225w)\n\n\nOctober 8\, 2026\n10:00–11:00\nMental Health and the Use of Psychotropic Medications in People with Intellectual and Developmental Disabilities in Castile and León.\nCarla Redondo Jimeno. \nHealth psychologist. Head of Social and Health Care Coordination at Plena inclusión CyL. (ID No.: 12413417H) \n\n\n\n8/10/2026\n11:00-11:45\nCommunity Support Model for People with Intellectual Disabilities and Behavioral Disorders. The Zamora Network Model. And User Evaluations \nManuel A. Franco Martín. \nPsychiatrist. Chief of the Department of Psychiatry and Mental Health at CAZA (ID No.: 09278225w)\n\n\n8/10/2026\n11:45-12:30\nSacyl Regional Reference Unit for Severe Behavioral and Acute Psychiatric Disorders at Santa Isabel Hospital in León: Clinical Profiles of Admitted Patients; Therapeutic Intervention Strategies; Clinical Case: The Complexity Requiring a Multidisciplinary Intervention. \nFrancisco Rodriguez Fernández. Psychiatrist . ( ID No.: 27383161M) Leticia Trigal García ( ID No.: 71713782N) Ana Cabezas Anido. Nurse (ID No.: 71435489L) Raquel Alonso Gómez\, Clinical Psychologist (ID No.: 71441971S)\, Cristina del Cano González\, Social Worker (ID No.: 09813908S) \nRegional Reference Unit for Behavioral Disorders in Intellectual Disabilities. León Healthcare Complex. \n\n\n8/10/2026\n12:30-13:15\nDual Pathology Unit for People with Intellectual Disabilities and Severe Behavioral Disorders. A Care and Educational Model for People with Intellectual Disabilities \n  \nFrom Social Services. Objectives and Expected Outcomes. \nVirginia Yagüe Gete \nHealth psychologist specializing in intellectual disabilities. Fundación Hospitalarias Palencia. (ID No.: 7289090L) \n \n\n\nOctober 8\, 2026\n1:15–2:00 p.m.\nThe Comprehensive Assessment Process for People with Intellectual Disabilities and Concerning Behaviors (Part I)\nRamon Novell Alsina. \nPsychiatrist specializing in mental health for people with intellectual disabilities. Former head of the mental health network specializing in intellectual disabilities in Girona\, Government of Catalonia (ID: 46516827V)\n\n\nOctober 8\, 2026\n3:30–4:30 p.m.\nThe Comprehensive Assessment Process for Individuals with Intellectual Disabilities and Behaviors of Concern (Part II)\nRamon Novell Alsina. \nPsychiatrist specializing in mental health for people with intellectual disabilities. Former head of the mental health network specializing in intellectual disabilities in Girona\, Government of Catalonia (ID: 46516827V)\n\n\n8/10/2026\n16:30-17:00\nBehavioral Disorder or Mental Illness: Challenges in Diagnosis and Treatment. \nManuel A. Franco Martín. \nPsychiatrist. Chief of the Department of Psychiatry and Mental Health at CAZA (ID No.: 09278225w)\n\n\n8/10/2026\n17:00-17:45\nDiagnostic Systems for Mental Illness in People with Intellectual Disabilities\nFrancisco Rodriguez Fernández. Psychiatrist . Regional Reference Unit for Behavioral Disorders in Intellectual Disabilities. León Healthcare Complex. (ID No.: 27383161M)\n\n\nOctober 8\, 2026\n5:45–6:30 p.m.\nMajor Mental Illnesses and Specific Characteristics in People with Intellectual Disabilities. \nCase study to work on at home.\nManuel A. Franco Martín. \nPsychiatrist. Chief of the Psychiatry and Mental Health Service at CAZA (ID No.: 09278225w)\n\n\nNovember 10\, 2026\n9:30–11:00\nIntroduction to the Comprehensive Support Model\nRamon Novell Alsina. \nPsychiatrist specializing in mental health for people with intellectual disabilities. Former head of the mental health network specializing in intellectual disabilities in Girona\, Government of Catalonia (ID: 46516827V)\n\n\n10/11/2026\n11:00-12:00\nThe Role of Antipsychotics in Mental (and Behavioral) Disorders Associated with Intellectual Disabilities: Proper Use and Risks. \nManuel A. Franco Martín. \nPsychiatrist. Chief of the Department of Psychiatry and Mental Health at CAZA (ID No.: 09278225w)\n\n\n10/11/2026\n12:00-12:30\nLong-acting injectable antipsychotics. Role in intellectual disability \nJuan García Mellado \nCoordinator of the Psychiatric Inpatient Unit at the Zamora Healthcare Complex (ID No.: 11950521C)\n\n\n10/11/2026\n12:30-13:00\nBenzodiazepines and Mood-Regulating Psychotropic Medications in Intellectual Disabilities\nFrancisco Rodriguez Fernández. Psychiatrist . Regional Reference Unit for Medium-Term Care for Intellectual Disabilities. León Healthcare Complex. (ID No.: 27383161M)\n\n\n10/11/2026\n1:00–1:30 p.m.\nOther Psychotropic Medications and Biological Treatments for Intellectual Disabilities\nDiscussion among the psychiatrists teaching the course about their previous experiences. And case reviews. \n\n\n10/11/2026\n13:30-14:00\nSTOP/STAMP. Strategies for Rationalizing the Use of Psychotropic Medications in Individuals with Intellectual Disabilities. \nRamon Novell Alsina. \nPsychiatrist specializing in mental health for people with intellectual disabilities. Former head of the mental health network specializing in intellectual disabilities in Girona\, Government of Catalonia (ID No.: 46516827V)\n\n\n10/11/2026\n15:30-18:00\nThe Positive Behavioral Support Model as a Psychotherapeutic Tool. 150 min \n· Primary and secondary prevention and reactive strategies \n· Person-Centered Planning \n· Low-activation strategies \n· Managing Stress and “Burnout” Among Professionals \n \nAinara Gómez Blanco. \nPsychologist. Director of the Plena Inclusión Mental Health Program in La Rioja (PPISAM). She is a member of the La Rioja mental health network. Director of the regional team responsible for assessing and designing support services for people with mental health and behavioral issues. (ID No.: 72789900Y)\n\n\nNovember 10\, 2026\n6:00–6:30 p.m.\nChanging Beliefs and Attitudes Toward People with Complex Behaviors\nCarla Redondo Jimeno. \nHealth psychologist. Head of Social and Health Care Coordination at Plena inclusión CyL. (ID No.: 12413417H) \n \n\n\n\n  \nSeats: \n\n\n20 free in-person spots. Reserved exclusively for individuals affiliated with a nonprofit organization serving people with intellectual disabilities and IBSAL professionals who are not part of Sacyl. \n\n\nUnlimited spots for live streaming at a cost of 20 euros.\n\n\n  \nEnrollment: \nREGISTRATION: \nNote: HUS staff who are not affiliated with IBSAL must register through the GESTION@FC training application: www.salud.jcyl.es/gestio@fc \nThe pre-registration period for IBSAL staff runs through Friday\, October 1\, via our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \nPlease note that you can only be considered registered for the course when you receive the confirmation email\, as there is a limit to the number of places available. \nSELECTION METHOD: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n  \n  \n  \nIBSAL TRAINING URL:https://ibsal.es/en/evento/mental-health-in-people-with-intellectual-disabilities-assessment-and-intervention/ CATEGORIES:Sacyl Course END:VEVENT BEGIN:VEVENT DTSTART;TZID=UTC:20261013T083000 DTEND;TZID=UTC:20261013T093000 DTSTAMP:20261001T112418Z CREATED:20261001T112418Z LAST-MODIFIED:20261001T112418Z UID:10002427-1791880200-1791883800@ibsal.es SUMMARY:PREDOC Seminar: Design\, Synthesis\, and Evaluation of Amphiphilic Antimitotics with Antitumor and Antiparasitic Activity DESCRIPTION:Presenter: Noelia Fernández Ceballos APSF-05 – Design and Synthesis of Bioactive Molecules (DOMOOBIO)\nDate: Tuesday\, October 13\, 2026\nTime: 8:30–9:30 a.m.\nLocation: Auditorium. School of Medicine\, University of Salamanca \n\n  URL:https://ibsal.es/en/evento/predoc-seminar-design-synthesis-and-evaluation-of-amphiphilic-antimitotics-with-antitumor-and-antiparasitic-activity/ LOCATION:Hall of Degrees. Faculty of Medicine of the University of Salamanca.\, C. Alfonso X el Sabio\, s/n\, Salamanca\, Salamanca\, 37007\, Spain CATEGORIES:Event ATTACH;FMTTYPE=image/png:https://ibsal.es/wp-content/uploads/2026/10/Seminario-predoc-13.10.2026.png END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20261019 DTEND;VALUE=DATE:20261020 DTSTAMP:20260724T062722Z CREATED:20260724T062722Z LAST-MODIFIED:20260724T062722Z UID:10002257-1792368000-1792454399@ibsal.es SUMMARY:FERO Cancer Calls for Proposals 2027 DESCRIPTION:Objective\nThe goal of these calls for proposals is to promote translational cancer research projects and support researchers at various stages of their scientific careers in order to accelerate advances that will transform the future of cancer. \n  \nHelp\n— FERO Cancer Fellowship for Young Researchers 2027\n— FERO Cancer Fellowship for Young Medical Researchers 2027\n— Dr. Josep Baselga FERO Cancer Scholarship 2027\n— FERO Pediatric Cancer Scholarship 2027\n— FERO Women’s Cancer Grant 2027\, for projects focused on cancers that affect women. (NEW) \n— FERO Lung Cancer Grant – The Ricky Rubio Foundation 2027\, a new call for proposals to accelerate lung cancer research. (NEW) \n  \nDeadlines\nThe call for applications is not yet open. The application period begins on October 19\, 2026; the closing date has not yet been set. An “info day” will be held to finalize the details. \n  \nInfo Day\nIn order to present the new features of this edition\, explain the changes made to the guidelines\, share the new schedule\, and answer any questions about the application process\, an Info Day will be held for researchers and institutions. \n\nDate: September 29\, 2026\nTime: 11:00 a.m.–12:00 p.m.\nFormat: Online\n\nThose interested can register via the following link to gain access to the session:\nhttps://forms.office.com/e/0JLwjfjHvg?origin=lprLink \nIf you have any questions\, please contact beca@ferocancer.org URL:https://ibsal.es/en/evento/fero-cancer-calls-for-proposals-2027/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20261020 DTEND;VALUE=DATE:20261021 DTSTAMP:20260930T081512Z CREATED:20260930T081512Z LAST-MODIFIED:20260930T081512Z UID:10002365-1792454400-1792540799@ibsal.es SUMMARY:Transcriptome Sequencing and Analysis DESCRIPTION:In-Person Course: “Transcriptome Sequencing and Analysis “ \n  \nObjective: \n\n\n\nThe overall objective of the course is for students to acquire a basic understanding of transcriptome sequencing and bioinformatics analysis. \n \n\n\n\n  \nSpecific objectives: \n\n\n\n Understand the main high-throughput sequencing techniques. \n– Recognize and use general-purpose databases in the field of transcriptome sequencing. \n– Access information from public transcriptome data repositories. \n– Perform bioinformatics analyses of transcriptomes using web-based tools.\n\n\n\nTuesday\, October 20\, 2026\, from 9:00 a.m. to 3:00 p.m. \n  \nLocation: \nSequencing Service. R&D&I Building\, 2 Espejo St. October 20\, 2026\, 9:00 a.m. – 11:00 a.m.\nComputer Lab 1 in the Dioscórides Building. Miguel de Unamuno Campus. October 20\, 2026\, from 11:00 a.m. to 3:00 p.m. \nProgram: \n\n\n\nCourse Date\nSchedule\nContent\nFirst Name\, Last Name\, ID Number\, and Qualification of the INSTRUCTOR\n\n\nOctober 20\, 2026 \n\n9:00 – 10:00\nIntroduction to Mass Sequencing.\nMaría Jara Acebedo. \n11964400F. \nPh.D. in molecular biology and head of the High-Throughput Sequencing Service at USAL.\n\n\nOctober 20\, 2026\n10:00 a.m. – 11:00 a.m.\nVisit to the Mass Sequencing Laboratory.\nMaría Jara Acebedo. \n11964400F. \nPh.D. in molecular biology and head of the Mass Sequencing Service at USAL.\n\n\nOctober 20\, 2026\n11:00 a.m. – 12:00 p.m.\nBioinformatics Applications and Resources in Transcriptomics.\nCarlos Prieto Sánchez. \n70865013N. \nPh.D. in Bioinformatics and Head of the Bioinformatics Service at USAL.\n\n\nOctober 20\, 2026\n12:00 PM – 12:30 PM\nAccess to experimental transcriptomics data. \n\nCarlos Prieto Sánchez. \n70865013N. \nPh.D. in Bioinformatics and Head of the Bioinformatics Service at USAL.\n\n\nOctober 20\, 2026\n12:30 p.m. – 3:00 p.m.\nTranscriptome Analysis with RaNA-Seq. \n\nCarlos Prieto Sánchez. \n70865013N. \nPh.D. in Bioinformatics and Head of the Bioinformatics Service at USAL.\n\n\n\nTwo-hour practice session \nEnrollment: \nREGISTRATION: \nThe registration deadline is Friday\, October 16\, 2026\, and registration must be done individually through our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \nPrice: \n0 euros. \nMethod of selection: \nEnrollment in the course will be on a first-come\, first-served basis\, as agreed by the IBSAL Training Committee\, with 15 spots reserved for IBSAL staff and 5 for HUS staff. \n  URL:https://ibsal.es/en/evento/transcriptome-sequencing-and-analysis/ CATEGORIES:IBSAL Course END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20261020 DTEND;VALUE=DATE:20261021 DTSTAMP:20261002T083844Z CREATED:20261002T083835Z LAST-MODIFIED:20261002T083844Z UID:10002430-1792454400-1792540799@ibsal.es SUMMARY:Scientific and Technical Sessions for Senior Clinical and Biomedical Diagnostic Technicians DESCRIPTION:Scientific and Technical Sessions for Senior Clinical and Biomedical Diagnostic Technicians \n  \nObjective: \nTo update knowledge on diagnostic procedures\, quality control\, and new laboratory tools. \n  \nSpecific objectives: \nTo analyze the quality control procedures applied to hematopoietic progenitor cells in the context of allogeneic transplantation. \nTo determine the diagnostic utility and clinical application of the GFAP and UCH&8209;L1 biomarkers in patients with mild acute brain injury. \nTo evaluate the utility of automated hematology systems and their correlation with conventional morphological methods. \n  \nDate: \nStart Date: September 21\, 2026 \nEnd: December 30\, 2026 \n  \nLocation: \nCAUSA DP0518 Auditorium \n  \nProgram: \n\n\n\nDate / Time\nLocation\nSpeaker\nContent\n\n\nSeptember 21\, 26\nCAUSA DP0518 AUDITORIUM\n– María Magdalena Barbero García\n– CORRELATION BETWEEN HEMOGLOBIN LEVELS MEASURED BY THE GEM 5000 WERFEN BLOOD GAS ANALYZER AND THE SIEMENS ADVIA 2120I CYTOMETER\n\n\n13:30 / 15:30\n\n\n10/26/19\nCAUSA DP0518 AUDITORIUM\n– REBECA ORTEGA HERRERA\n– QUALITY CONTROL OF HEMATOPOIETIC PROGENITOR CELLS USING CLONOGENIC ASSAYS IN THE CONTEXT OF ALLOGENEIC TRANSPLANTATION. \nFUNCTIONAL COMPARISON OF FRESH VERSUS CRYOPRESERVED PROGENITOR CELLS\n\n\n13:30 / 15:30\n\n\n11/23/26\nCAUSA DP0518 AUDITORIUM\n– SOFIA GONZALEZ MARTIN\n– DETERMINATION OF BIOMARKERS FOR MILD ACUTE BRAIN INJURY IN THE EMERGENCY ROOM LABORATORY: GFAP AND UCH-L1\n\n\n13:30 / 15:30\n\n\n12/14/26\nCAUSA DP0518 AUDITORIUM\n– MARIA DE LOS ANGELES GOMEZ GONZALEZ\n– CORRELATION BETWEEN THE ADVIA 2120 AUTOMATED LEUKOCYTE DIFFERENTIAL COUNT AND THE MORPHOLOGICAL COUNT ASSISTED BY CELIAVISION\n\n\n13:30 / 15:30\n\n\n\nEnrollment: \nREGISTRATION: \nIndividually\, through our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \nSeats: \n30 for IBSAL staff \nMethod of selection: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. \n  URL:https://ibsal.es/en/evento/scientific-and-technical-sessions-for-senior-clinical-and-biomedical-diagnostic-technicians-2/ CATEGORIES:IBSAL Course END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20261022 DTEND;VALUE=DATE:20261023 DTSTAMP:20260928T114319Z CREATED:20260921T130854Z LAST-MODIFIED:20260928T114319Z UID:10002420-1792627200-1792713599@ibsal.es SUMMARY:"Multidisciplinary Forum on Liver Cancer" DESCRIPTION:In-Person “Multidisciplinary Forum on Liver Cancer” \nObjective: \nTo improve clinical decision-making in liver cancer by integrating evidence\, multidisciplinary expertise\, and consensus applied to complex clinical scenarios. \nSpecific objectives: \nTo analyze real-world cases of HCC and intrahepatic CCA; update diagnostic and therapeutic criteria; discuss alternatives in borderline cases; integrate a multidisciplinary and patient-centered approach; and establish regional consensus criteria that promote consistent and equitable care. \nDate: \nThursday\, October 22\, 2026. \nLocation: \nAuditorium of the University Healthcare Complex of Salamanca and the International Spanish Language Center. \nProgram: \n\n\n\nSCIENTIFIC LECTURE SERIES — TRANSLATIONAL SCIENCE \n \n\n\n22/10/26\n9:20 a.m.\n\nOPENING LECTURE: “Translational Research in Liver Cancer: Salamanca\, a Hub of Innovation”\nProf. José Juan García Marín\, Full Professor · Department of Physiology and Pharmacology · USAL · Head of the HEVEFHARM Group\, CIBEREHD. \n\n\n22/10/26\n9:50 a.m.\n“Moving Forward Together in Cholangiocarcinoma: The Value of Collaborative Networks”\nProf. Rocío I. R. Macías \nProfessor · Department of Physiology and Pharmacology · USAL · Coordinator of the COST Precision-BTC Network. \n\n\n10/22/26\n10:15 a.m.\n“Immunotherapy and New Therapeutic Strategies for Liver Cancer”\nDr. Pedro Berraondo \nPrincipal Investigator · Cytokine-Based Therapies Group · CIMA · University of Navarra Clinic.\n\n\n10/22/26\n10:40\nOPEN DISCUSSION WITH THE AUDIENCE (15 min)\n\n\n\n11:00 \nCoffee break \n \n\n\nCOMMUNITY — MEETING WITH PATIENTS AND FAMILIES · 11:30 a.m.–2:00 p.m. \n \n\n\n22/10/26\n11:30 a.m.\nSESSION A · 30 min — PRESENTATION BY ORGANIZATIONS \n  \n  \nPETHCyL Association — People with Liver Disease and Liver Transplant Recipients in CYL. Magdalena Alejo. \n· ATUVIBI Association — Biliary Tract Diseases and Tumors. President: Elisabeth Baucells. \n  \n· Work\, mission\, support\, and healthcare dialogue in the Community of Castile and León and at the national level \n \n\n\n\n22/10/26\n12:00\nBLOCK B · 60 min — MULTIDISCIPLINARY OPEN DIALOGUE \n: Improving Clinical Care and Communication: AEEH Care Guidelines for Liver Disease \n \nInmaculada Sánchez\, Nursing. Gastroenterology Department. Pilar Carreto\, Psychologist\, AECC-Salamanca. \n· Lessons in Nutrition · Elena Delgado and Natalia Ramos\, Nurse and Nutritionist. Endocrinology Department \n\n\n22/10/26\n13:00\nBLOCK C · 60 min — THE PATIENT’S PERSPECTIVE ON HCC\, CCA\, AND TRANSPLANTATION \nThe journey from diagnosis to treatment decision. \n· Shared decision-making with the medical team. \n· The transplant experience: waiting\, the process\, and life after transplant \n· Unmet needs and their impact on life plans.\nA group discussion took place among all attendees\, facilitated by the nursing staff and physicians \n \n\n\n3:30 p.m. \nMEETING PLACE: WELCOME COCKTAILS AND COFFEE · CIE-USAL\n\n\n  \n16:30-20:45 \nPLENARY SESSION \nBorder Scenarios · Complex Decisions · Consensus and Networking \nModerators: Dr. J. González · Dr. A. Matilla · Dr. C. Esteban · Dr. A. López \nLive Vote: Surgery/Transplant\, Locoregional\, Systemic\, Uncertain/Alternative \nGuest panelists from Radiodiagnostics · Hepatology · Oncology · Surgery · Interventional Radiology · Nuclear Medicine\n\n\n22/10/26\n16:30\nSCENARIO 1 — HCC OUTSIDE THE “UP-TO-7” CRITERIA \nNeoadjuvant therapy and decision on surgery/transplant \n· Downstaging: dual IO vs. IO + anti-VEGF \n· Dynamic selection · Transplant vs. resection after response \n \n\n\n\n22/10/26\n17:30\nSCENARIO 2 — INTERMEDIATE HCC: TACE vs. TARE vs. Early Systemic Therapy \n· TACE—not eligible or TACE-refractory \n· Window for dual IO vs. IO + anti-VEGF · Conversion to curative therapy \n6:30 PM (60 min) 🔷 SCENARIO\n\n\n\n10/22/26\n6:30 p.m.\nSCENARIO 3 — ADVANCED HCC WITH RESPONSE: Conversion\, Adjuvant Therapy\, and Surgical Rescue \n· Conversion therapies: dual IO vs. IO + anti-VEGF \n· Post-response surgery · TALENT model · Post-resection adjuvant therapy\n\n\n\n10/26/22\n7:30 p.m.\nSCENARIO 4 — BORDERLINE CHOLANGIOCARCINOMA Endoscopic evaluation · Combined strategy · Surgical rescue \n· TOPAZ-1: durvalumab + QT as standard \n· TARE in intrahepatic cholangiocarcinoma · Conversion to resection or transplantation\n\n\n\nINTEGRATIVE CLOSING SESSION — CONSENSUS · 8:30 p.m. · 15 min \nSummary of decisions by scenario · Proposal for a liver cancer network.\n\n\n\nSeats: \n75 positions for IBSAL staff \nEnrollment: \nNote: HUS staff who are not affiliated with IBSAL must register through the GESTION@FC training application: www.salud.jcyl.es/gestio@fc \nThe registration deadline is Tuesday\, October 20\, 2026; you can register individually through our website. \nIn order to successfully complete the course and receive the relevant certificate\, it is necessary to complete 80% of the total program. \nPlease note that you can only be considered registered for the course when you receive the confirmation email\, as there is a limit to the number of places available. \nSELECTION METHOD: \nEnrollment in the course will be carried out in strict order of enrollment (in courses with high demand\, preference will be given to IBSAL personnel)\, according to the agreement of the IBSAL Training Commission. URL:https://ibsal.es/en/evento/multidisciplinary-forum-on-liver-cancer/ CATEGORIES:Course ATTACH;FMTTYPE=image/png:https://ibsal.es/wp-content/uploads/2026/09/Foro_HCC_cartel-1.pdf-2.png END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20270210 DTEND;VALUE=DATE:20270922 DTSTAMP:20260921T113822Z CREATED:20260225T064245Z LAST-MODIFIED:20260921T113822Z UID:10002238-1802217600-1821571199@ibsal.es SUMMARY:Horizon Europe. Cancer Mission 2026 and 2027 DESCRIPTION:Features\nThe work program for the Cancer Missions under Horizon Europe for 2026 and 2027. \nThese are single-phase calls for proposals\, aimed at international multidisciplinary consortia\, which must submit a proposal in accordance with the specifications for each topic. \nAdmission requirements\, eligibility criteria\, and the necessary documents are described in the General Annexes. \n  \nThese are the topics included in the Cancer Mission’s new Work Program for the year 2026: \nThese topics are single-phase: they begin on February 10\, 2026\, and end on September 15\, 2026. \nHORIZON-MISS-2026-02-CANCER-01: Virtual Human Twin (VHT) Models for Cancer Research \nHORIZON-MISS-2026-02-CANCER-02: Microbiome for Early Cancer Prediction Before the Onset of Disease \n\nHORIZON-MISS-2026-02-CANCER-03: Pragmatic clinical trials to optimize immunotherapy interventions for patients with refractory cancers \nHORIZON-MISS-2026-02-CANCER-04: Earlier and More Precise Palliative Care \nHORIZON-MISS-2026-02-CANCER-05: Improving the mental health of young cancer survivors through the European Cancer Patient Digital Centre (ECPDC) \nHORIZON-MISS-2026-02-CANCER-06: Development of a research capacity-building program on cancer with and for Ukraine (csa) \nHORIZON-MISS-2026-02-CANCER-07: Improve the Quality of Life of Older Cancer Patients \n\nA very interesting topic in the “Soil Deal for Europe” section\, which opens on February 4\, 2026\, and closes on September 23\, 2026: \nHORIZON-MISS-2026-05-SOIL-02: Antimicrobial Resistance and Antibiotic Biosynthesis in Soils: Developing Key Insights and Countermeasures Using a One-Health Approach \n  \nThese are the topics included in the Cancer Mission’s new Work Program for the year 2027: \nThese topics are single-phase: they begin on February 10\, 2027\, and end on September 21\, 2027. \nHORIZON-MISS-2027-02-CANCER-01: Leveraging functional genomics to identify novel targets for cancer treatment \nHORIZON-MISS-2027-02-CANCER-02: Clinical research conducted by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers \nHORIZON-MISS-2027-02-CANCER-03: Phase 1\, including first-in-human clinical trials to test biomarker-guided medicines or multimodal treatment interventions for patients with rare or very rare cancers or cancer subtypes \nHORIZON-MISS-2027-02-CANCER-04: Improving equitable health outcomes and added value for and with cancer patients through health economics research\, health systems research\, and outcomes research \nHORIZON-MISS-2027-02-CANCER-05: Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies\, cancer medical devices\, or cancer medicines \nHORIZON-MISS-2027-02-CANCER-06: Support for a research program on the quality of life (QoL) of young cancer survivors\, led by cancer charities and funding agencies (csa) \nThis is a very interesting topic—a Joint Call for Missions. The call opens on February 4\, 2027\, and closes on September 21\, 2027: \nHORIZON-MISS-2027-06-SOIL-CANCER: Living labs to monitor and mitigate carcinogenic substances in and originating from soils: Evaluating their effects on human cancer risks \n  \n**If you’re interested in any of our job openings or need more information\, please don’t hesitate to contact us. \n\n\n\nRequirements:\nThese calls for proposals are aimed at multidisciplinary European consortia. Unless otherwise specified in the specific conditions of the call\, only legal entities that form a consortium will be eligible to participate in the actions\, provided that the consortium includes\, as beneficiaries\, three legal entities that are independent of one another\, each established in a different country\, in accordance with the following criteria: \n\n\nat least one independent legal entity established in a Member State; and \n\n\nat least two other independent legal entities\, each established in different Member States or Associated Countries. \n\n\nLegal entities established in Russia\, Belarus\, or in territories of Ukraine not controlled by the government are not eligible. \nHow to apply\nApplications consist of two sections: \n-Part A (to be completed online) contains administrative information related to the consortium\, the budget\, and specific details of the call for proposals. \n-Part B (a template downloaded from the Commission’s website must be completed) contains the scientific and technical aspects of the project. \n  \nSubmission deadline.\nThe 2026 application deadlines are September 15\, and the process is a single-stage process\, With the exception of call HORIZON-MISS-2026-05-SOIL-02\, which ends on September 23\, 2026. \nThe application deadlines for 2027 are September 21\, 2027\, and the application process consists of a single stage. URL:https://ibsal.es/en/evento/horizon-europe-cancer-mission-2026-and-2027/ CATEGORIES:Calls for research END:VEVENT BEGIN:VEVENT DTSTART;VALUE=DATE:20270210 DTEND;VALUE=DATE:20270923 DTSTAMP:20260513T105706Z CREATED:20260513T105706Z LAST-MODIFIED:20260513T105706Z UID:10002229-1802217600-1821657599@ibsal.es SUMMARY:Horizon Europe. Cluster 1: Health 2027 DESCRIPTION:Features\nThe work program for Cluster 1 (Health) under Horizon Europe has been published: Horizon Europe Cluster 1 Health Work Program for 2027. It falls within the framework of the new Horizon Europe strategic plan for the 2025–2027 period. The main priorities focus on social cohesion\, inclusion\, and the overall health and well-being of Europeans\, in line with the European Pillar of Social Rights. Other key priorities include the need to modernize health care systems and to support an innovative\, sustainable\, and competitive health industry in Europe. \nMore specifically\, Cluster 1 strives to contribute to six expected impacts as set forth in the Strategic Plan\, which are distributed across the following topics: \nList of calls for applications that open on February 10\, 2027\, and close on April 13\, 2027: \n\nDestination – Staying Healthy in a Rapidly Changing Society \nHORIZON-HLTH-2027-01-STAYHLTH-01: Addressing Disabilities Throughout the Life Course to Support Independent Living and Inclusion \nDestination – Living and Working in a Health-Promoting Environment \nHORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterizing its changes in response to climate change \nHORIZON-HLTH-2027-01-ENVHLTH-MISSCLIMA-03: Tools and technologies to support health adaptation to climate change \nDestination – Tackling Diseases and Reducing the Disease Burden \nHORIZON-HLTH-2027-01-DISEASE-05: Development of novel small-molecule antiviral therapeutics for pathogens with epidemic potential \nHORIZON-HLTH-2027-01-DISEASE-06: Development of Monoclonal Antibodies to Prevent and Treat Infections Caused by Flaviviruses \nHORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections caused by Filo-\, Nairo-\, Phenui-\, Picorna-\, and Toga viruses \nHORIZON-HLTH-2027-01-DISEASE-08: Development of Innovative Antimicrobials Against Antimicrobial-Resistant Pathogens \nHORIZON-HLTH-2027-01-DISEASE-10: Prevention and Management of Chronic Noncommunicable Diseases in Children and Young People (GACD) \nDestination – Ensuring equal access to innovative\, sustainable\, and high-quality healthcare \nHORIZON-HLTH-2027-01-CARE-02: Personalized Approaches to Reduce Risks from Adverse Drug Reactions Resulting from the Administration of Multiple Medications \n\nDestination – Maintaining an innovative\, sustainable\, and competitive EU healthcare industry \nHORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for the discovery and/or production of biologics \n  \nList of two-phase calls for proposals opening on February 10\, 2027. The first phase closes on April 13\, 2027\, and the second phase closes on September 22\, 2027: \nDestination – Tackling Diseases and Reducing the Disease Burden \nHORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for noncommunicable diseases \nHORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials to advance innovative interventions for neurodegenerative diseases \nDestination – Developing and using new tools\, technologies\, and digital solutions for a healthy society \nHORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers for disease progression and treatment response using AI methodologies for chronic noncommunicable diseases \nDestination – Maintaining an innovative\, sustainable\, and competitive EU healthcare industry \nHORIZON-HLTH-2027-02-IND-02-two-stage: Portable and Versatile Point-of-Care Diagnostics \n  \nList of calls for applications that open on June 3\, 2027\, and close on September 22\, 2027: \nDestination – Developing and using new tools\, technologies\, and digital solutions for a healthy society \nHORIZON-HLTH-2027-03-TOOL-02: Advancing the bioprinting of living cells for regenerative medicine \nHORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for Integrated Clinical Decision Support in Prevention and Diagnosis \nHORIZON-HLTH-2027-03-TOOL-08: Toward Artificial General Intelligence (AGI) for Healthcare \n  \n**If you’re interested in any of our job openings or need more information\, please don’t hesitate to contact us. \n\n\n\nRequirements:\nThese calls for proposals are aimed at multidisciplinary European consortia. Unless otherwise specified in the specific conditions of the call\, only legal entities that form a consortium will be eligible to participate in the actions\, provided that the consortium includes\, as beneficiaries\, three legal entities that are independent of one another\, each established in a different country\, in accordance with the following criteria: \n\n\nat least one independent legal entity established in a Member State; and \n\n\nat least two other independent legal entities\, each established in different Member States or Associated Countries. \n\n\nLegal entities established in Russia\, Belarus\, or in territories of Ukraine not controlled by the government are not eligible. \nHow to apply\nApplications consist of two sections: \n-Part A (to be completed online) contains administrative information related to the consortium\, the budget\, and specific details of the call for proposals. \n-Part B (a template downloaded from the Commission’s website must be completed) contains the scientific and technical aspects of the project. URL:https://ibsal.es/en/evento/horizon-europe-cluster-1-health-2027/ CATEGORIES:Calls for research END:VEVENT END:VCALENDAR